Literature DB >> 9640997

Efficacy studies of paroxetine in panic disorder.

R B Lydiard1, M Steiner, D Burnham, I Gergel.   

Abstract

The optimal assessment of treatment outcome for studies assessing the efficacy of treatments for panic disorder has been a controversial topic. A recent National Institute of Mental Health (NIMH)-sponsored consensus conference addressed this important topic, and a summary paper regarding assessment of essential elements of the disorder resulted. Among other conclusions, it was agreed that several different domains should be considered as essential. This article reviews three pivotal studies assessing the efficacy of paroxetine for the treatment of panic disorder, and evaluates these studies for inclusion of those variables considered essential. Additionally, some data were reanalyzed to determine the percentage of individuals in these studies who are unequivocal responders (i.e., were both panic-free and rated on global assessment as responders). A longer-term treatment and relapse study is also mentioned briefly.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9640997

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  3 in total

1.  Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.

Authors:  Naomi M Simon; Michael W Otto; John J Worthington; Elizabeth A Hoge; Elizabeth H Thompson; Richard T Lebeau; Samantha J Moshier; Alyson K Zalta; Mark H Pollack
Journal:  J Clin Psychiatry       Date:  2009-10-06       Impact factor: 4.384

2.  Venlafaxine in the treatment of panic disorder.

Authors:  Martin A Katzman; Leslie Jacobs
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

3.  Three year naturalistic outcome study of panic disorder patients treated with paroxetine.

Authors:  Pinhas N Dannon; Iulian Iancu; Ami Cohen; Katherine Lowengrub; Leon Grunhaus; Moshe Kotler
Journal:  BMC Psychiatry       Date:  2004-06-11       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.